Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022
Data demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy
CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. The abstract title has been posted to the AACR Online Itinerary Planner, will be published in the online Proceedings of the AACR, and is detailed below.
The data to be presented demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy in a human leukocyte antigen (HLA)-matched, allogeneic patient-derived xenograft (PDX) melanoma model, including greater persistence of cytoTIL15 cells in blood and lymphoid organs, superior tumor growth inhibition including complete responses, and increased infiltration of tumors with cytoTIL15 cells.
"We look forward to presenting these new data at AACR, which continue to validate the exciting potential of our cytoTIL15 therapy to improve the treatment of patients with solid tumors," said Jan ter Meulen, M.D., Ph.D., Chief Scientific Officer at Obsidian Therapeutics. "We are encouraged by the data demonstrating superior anti-tumor activity of cytoTIL15 cells in the absence of IL2 in a novel PDX tumor model. These data deliver preclinical proof of concept for the potential of cytoTIL15 therapy as a treatment for metastatic melanoma and will support the planned filing of an IND for our lead program, OBX-115, later this year."
Details of the poster presentation are as follows:
Abstract Number: 7994
About Obsidian Therapeutics
View original content to download multimedia:https://www.prnewswire.com/news-releases/obsidian-therapeutics-to-present-preclinical-data-from-cytotil15-program-at-the-american-associate-of-cancer-research-aacr-annual-meeting-2022-301522445.html
SOURCE Obsidian Therapeutics